Types of observations that can be made about Preferences.

A sequence of values in the "absolute" time domain. This is the same time domain that all HL7 timestamps use. It is time as measured by the Gregorian calendar

Identifies types of detectyed issues for Act class "ALRT" for the administrative and patient administrative acts domains.

**Description:**Provides a categorization for annotations recorded directly against the patient .

Definition: Characterizes how a patient was or will be transported to the site of a patient encounter.

Examples: Via ambulance, via public transit, on foot.

Describes the artificial blood identifier that is associated with the specimen.

Identifies the type of observation that is made about a specimen that may affect its processing, analysis or further result interpretation

An observation that reports the dilution of a sample.

Domain provides codes that qualify the ActLabObsEnvfctsCode domain. (Environmental Factors)

An observation that relates to factors that may potentially cause interference with the observation

An observation that reports the volume of a sample.

Identifies types of detected issues regarding the administration or supply of an item to a patient.

Administration of the proposed therapy may be inappropriate or contraindicated as proposed

Admitting diagnosis are the diagnoses documented for administrative purposes as the basis for a hospital admission.

Proposed therapy is outside of the standard practice for an adult patient.

Indicates that the observation is of an unexpected negative occurrence in the subject suspected to result from the subject's exposure to one or more agents. Observation values would be the symptom resulting from the reaction.

Proposed therapy may be inappropriate or contraindicated due to patient age

**Definition:**Age at onset of associated adverse event; no implied method of determination.

**Definition:**Calculated age.

**Definition:**General specification of age with no implied method of determination.

**Definition:**Estimated age.

**Definition:**Reported age.

Indicates that the observation is carrying out an aggregation calculation, contained in the value element.

Communication of an agent from a living subject or environmental source to a living subject through indirect contact via oral or nasal inhalation.

Hypersensitivity to an agent caused by an immunologic response to an initial exposure

Proposed therapy may be inappropriate or contraindicated because of a recorded patient allergy to the proposed product. (Allergies are immune based reactions.)

**Definition:**The requested action has already been performed and so this request has no effect

A comprehensive term for health care provided in a healthcare facility (e.g. a practitioneraTMs office, clinic setting, or hospital) on a nonresident basis. The term ambulatory usually implies that the patient has come to the location and is not assigned to a bed. Sometimes referred to as an outpatient encounter.

Communication of an agent from one animal to another proximate animal.

Communication of an agent from an animal to a proximate person.

Description: Indicates the valid antigen count.

Description: Indicates whether an antigen is valid or invalid.

**Description:**Refines classCode OBS to indicate an observation in which observation.value contains a finding or other nominalized statement, where the encoded information in Observation.value is not altered by Observation.code. For instance, observation.code="ASSERTION" and observation.value="fracture of femur present" is an assertion of a clinical finding of femur fracture.

The dilution of a sample performed by automated equipment. The value is specified by the equipment

The dilution of a sample performed by automated equipment. The value is specified by the equipment

The available quantity of specimen. This is the current quantity minus any planned consumption (e.g., tests that are planned)

Communication of an agent to a living subject through direct contact with blood or blood products whether the contact with blood is part of a therapeutic procedure or not.

Communication of an agent from one living subject to another living subject through direct contact with any body fluid.

**Description:**A local business rule relating multiple elements has been violated.

An observation that states whether the disease was likely acquired outside the jurisdiction of observation, and if so, the nature of the inter-jurisdictional relationship.

OpenIssue: This code could be moved to LOINC if it can be done before there are significant implemenations using it.

**Definition:**An observation that provides a characterization of the level of harm to an investigation subject as a result of a reaction or event.

Code for the mechanism by which disease was acquired by the living subject involved in the public health case. Includes sexually transmitted, airborne, bloodborne, vectorborne, foodborne, zoonotic, nosocomial, mechanical, dermal, congenital, environmental exposure, indeterminate.

An observation that states the mechanism by which disease was acquired by the living subject involved in the public health case.

OpenIssue: This code could be moved to LOINC if it can be done before there are significant implemenations using it.

Description: The class room associated with the patient during the immunization event.

Summary of relevant clinical guidelines or other clinical recommendations supporting this eMeasure.

FDA label coating

Definition: A characteristic of an oral solid dosage form of a medicinal product, indicating whether it has one or more coatings such as sugar coating, film coating, or enteric coating. Only coatings to the external surface or the dosage form should be considered (for example, coatings to individual pellets or granules inside a capsule or tablet are excluded from consideration).

Constraints: The Observation.value must be a Boolean (BL) with true for the presence or false for the absence of one or more coatings on a solid dosage form.

**Description:**The specified code has been deprecated and should no longer be used. Select another code from the code system.

**Description:**The specified code is not valid against the list of codes allowed for the element.

FDA label color

Definition: A characteristic of an oral solid dosage form of a medicinal product, specifying the color or colors that most predominantly define the appearance of the dose form. SPLCOLOR is not an FDA specification for the actual color of solid dosage forms or the names of colors that can appear in labeling.

Constraints: The Observation.value must be a single coded value or a list of multiple coded values, specifying one or more distinct colors that approximate of the color(s) of distinct areas of the solid dosage form, such as the different sides of a tablet or one-part capsule, or the different halves of a two-part capsule. Bands on banded capsules, regardless of the color, are not considered when assigning an SPLCOLOR. Imprints on the dosage form, regardless of their color are not considered when assigning an SPLCOLOR. If more than one color exists on a particular side or half, then the most predominant color on that side or half is recorded. If the gelatin capsule shell is colorless and transparent, use the predominant color of the contents that appears through the colorless and transparent capsule shell. Colors can include: Black;Gray;White;Red;Pink;Purple;Green;Yellow;Orange;Brown;Blue;Turquoise.

**Description:**Proposed therapy may be inappropriate or contraindicated because of a common but non-patient specific reaction to the product.

**Example:**There is no record of a specific sensitivity for the patient, but the presence of the sensitivity is common and therefore caution is warranted.

**Description:**The proposed therapy is frequently misused or abused and therefore should be used with caution and/or monitoring.

There may be an issue with the patient complying with the intentions of the proposed therapy

An attribute of a quality measure describing the weight this component measure score is to carry in determining the overall composite measure final score. The value is real value greater than 0 and less than 1.0. Each component measure score will be multiplied by its CMPMSRSCRWGHT and then summed with the other component measures to determine the final overall composite measure score. The sum across all CMPMSRSCRWGHT values within a single composite measure SHALL be 1.0. The value assigned is scoped to the composite measure referencing this component measure only.

Indicates what method is used in a quality measure to combine the component measure results included in an composite measure.

Proposed therapy may be inappropriate or contraindicated due to an existing/recent patient condition or diagnosis

**Description:**The specified element must be specified with a non-null value under certain conditions. In this case, the conditions are true but the element is still missing or null.

The quantity of specimen that is used each time the equipment uses this substance

Identifies the organization(s) who own the intellectual property represented by the eMeasure.

A clinical judgment as to the worst case result of a future exposure (including substance administration). When the worst case result is assessed to have a life-threatening or organ system threatening potential, it is considered to be of high criticality.

The current quantity of the specimen, i.e., initial quantity minus what has been actually used.

Description of individual terms, provided as needed.

Criteria for specifying the entities to be evaluated by a specific quality measure, based on a shared common set of characteristics (within a specific measurement set to which a given measure belongs). The denominator can be the same as the initial population, or it may be a subset of the initial population to further constrain it for the purpose of the eMeasure. Different measures within an eMeasure set may have different denominators. Continuous Variable eMeasures do not have a denominator, but instead define a measure population.

Criteria which specify the removal of a subject, procedure or unit of measurement from the denominator, only if the numerator criteria are not met. Denominator exceptions allow for adjustment of the calculated score for those providers with higher risk populations. Denominator exceptions are used only in proportion eMeasures. They are not appropriate for ratio or continuous variable eMeasures. Denominator exceptions allow for the exercise of clinical judgment and should be specifically defined where capturing the information in a structured manner fits the clinical workflow. Generic denominator exception reasons used in proportion eMeasures fall into three general categories:

• Medical reasons
• Patient (or subject) reasons
• System reasons

Criteria which specify subjects who should be removed from the eMeasure population and denominator before determining if numerator criteria are met. Denominator exclusions are used in proportion and ratio measures to help narrow the denominator.

There is a clinical issue for the therapy that makes continuation of the therapy inappropriate.

Open Issue: The definition of this code does not correctly represent the concept space of its specializations (children)

**Description:**A note that is specific to a patient's diagnostic images, either historical, current or planned.

Discharge diagnosis are the diagnoses documented for administrative purposes as the time of hospital discharge.

Disclaimer information for the eMeasure.

Proposed dosage instructions for therapy differ from standard practice.

**Description:**Proposed dosage is inappropriate due to patient's medical condition.

Proposed length of therapy differs from standard practice.

Proposed length of therapy is longer than standard practice

Proposed length of therapy is longer than standard practice for the identified indication or diagnosis

Proposed length of therapy is shorter than that necessary for therapeutic effect

Proposed length of therapy is shorter than standard practice for the identified indication or diagnosis

Proposed dosage interval/timing differs from standard practice

Proposed dosage interval/timing differs from standard practice for the identified indication or diagnosis

**Description:**Proposed therapy may be contraindicated or ineffective based on an existing or recent drug therapy.

An allergy to a pharmaceutical product.

Proposed therapy may interact with an existing or recent drug therapy

Hypersensitivity resulting in an adverse reaction upon exposure to a drug.

Hypersensitivity to an agent caused by a mechanism other than an immunologic response to an initial exposure

**Description:**The proposed therapy appears to have the same intended therapeutic benefit as an existing therapy and uses the same mechanisms of action as the existing therapy.

The ID of the patient, order, etc., already exists. Used in response to addition transactions (Admit, New Order, etc.).

**Description:**The proposed therapy appears to have the same intended therapeutic benefit as an existing therapy, though the specific mechanisms of action vary.

The proposed therapy appears to duplicate an existing therapy

**Description:**More than one element with the same value exists in the set. Duplicates not permission in this set in a set.

This Observation Series type contains waveforms of a "representative beat" (a.k.a. "median beat" or "average beat"). The waveform samples are measured in relative time, relative to the beginning of the beat as defined by the Observation Series effective time. The waveforms are not directly acquired from the subject, but rather algorithmically derived from the "rhythm" waveforms.

This Observation type contains ECG "rhythm" waveforms. The waveform samples are measured in absolute time (a.k.a. "subject time" or "effective time"). These waveforms are usually "raw" with some minimal amount of noise reduction and baseline filtering applied.

Description: Element in submitted message will not persist in data storage based on detected issue.

A patient encounter that takes place at a dedicated healthcare service delivery location where the patient receives immediate evaluation and treatment, provided until the patient can be discharged or responsibility for the patient's care is transferred elsewhere (for example, the patient could be admitted as an inpatient or transferred to another facility.)

Proposed therapy may be inappropriate or ineffective because the end of administration is too close to another planned therapy

**Definition:**Proposed therapy may be inappropriate or ineffective because the end of administration is too close to another planned therapy.

An allergy to a substance other than a drug or a food. E.g. Latex, pollen, etc.

Communication of an agent from an environmental surface or source to a living subject by direct contact.

Hypersensitivity resulting in an adverse reaction upon exposure to environmental conditions.

Hypersensitivity to an agent caused by a mechanism other than an immunologic response to an initial exposure

**Definition:**The therapy is being performed at a time which diverges from the time the therapy was requested

FDA label data

Communication of an agent from a living subject or environmental source to a living subject through oral contact with material contaminated by person or animal fecal material.

The Fibrin Index of the specimen. In the case of only differentiating between Absent and Present, recommend using 0 and 1

A patient encounter that takes place both outside a dedicated service delivery location and outside a patient's residence. Example locations might include an accident site and at a supermarket.

The timestamp when the eMeasure was last packaged in the Measure Authoring Tool.

Communication of an agent from an non-living material to a living subject through direct contact.

An allergy to a substance generally consumed for nutritional purposes.

Proposed therapy may interact with certain foods

Hypersensitivity resulting in an adverse reaction upon exposure to food.

Hypersensitivity to an agent caused by a mechanism other than an immunologic response to an initial exposure

Communication of an agent from a food source to a living subject via oral consumption.

**Definition:**The therapy being performed is in some way out of alignment with the requested therapy.

Proposed therapy may be inappropriate or contraindicated due to patient gender.

Description: A DNA segment that contributes to phenotype/function. In the absence of demonstrated function a gene may be characterized by sequence, transcription or homology

**Description:**A general or uncategorized note.

Proposed therapy may be inappropriate or contraindicated due to patient genetic indicators.

Description: None provided

Proposed therapy is outside of standard practice for a geriatric patient.

Description: Accuracy determined as per the GIS tier code system.

Description: The school grade or level the patient was in when immunized.

Used to allow measure developers to provide additional guidance for implementers to understand greater specificity than could be provided in the logic for data criteria.

Location(s) in which care being measured is rendered

Usage Note: MSRSET is used rather than RoleCode because the setting applies to what is being measured, as opposed to participating directly in the health quality measure documantion itself).

Information on whether an increase or decrease in score is the preferred result. This should reflect information on which way is better, an increase or decrease in score.

**Definition:**There should be no actions taken in fulfillment of a request that has been held or suspended.

An observation of the hemolysis index of the specimen in g/L

Proposed dosage exceeds standard practice

Proposed dosage exceeds standard practice for the patient's age

Proposed dosage exceeds standard practice for the patient's height or body surface area

Proposed dosage exceeds standard practice for the patient's weight

**Description:**Accommodation type. In Intent mood, represents the accommodation type requested. In Event mood, represents accommodation assigned/used. In Definition mood, represents the available accommodation type.

Healthcare encounter that takes place in the residence of the patient or a designee

Indicates that the observation is of a person’s living situation in a household including the household composition and circumstances.

Communication of an agent from a person to a proximate person.

An observation that describes the icterus index of the specimen. It is recommended to use mMol/L of bilirubin

**Description:**The request is missing elements or contains elements which cause it to not meet the legal standards for actioning.

Description: A characteristic representing a single file reference that contains two or more views of the same dosage form of the product; in most cases this should represent front and back views of the dosage form, but occasionally additional views might be needed in order to capture all of the important physical characteristics of the dosage form. Any imprint and/or symbol should be clearly identifiable, and the viewer should not normally need to rotate the image in order to read it. Images that are submitted with SPL should be included in the same directory as the SPL file.

A note that is specific to a patient's immunizations, either historical, current or planned.

Description: Observation codes which describe characteristics of the immunization material.

Definition: A characteristic of an oral solid dosage form of a medicinal product, specifying the alphanumeric text that appears on the solid dosage form, including text that is embossed, debossed, engraved or printed with ink. The presence of other non-textual distinguishing marks or symbols is recorded by SPLSYMBOL.

Examples: Included in SPLIMPRINT are alphanumeric text that appears on the bands of banded capsules and logos and other symbols that can be interpreted as letters or numbers.

Constraints: The Observation.value must be of type Character String (ST). Excluded from SPLIMPRINT are internal and external cut-outs in the form of alphanumeric text and the letter 'R' with a circle around it (when referring to a registered trademark) and the letters 'TM' (when referring to a 'trade mark'). To record text, begin on either side or part of the dosage form. Start at the top left and progress as one would normally read a book. Enter a semicolon to show separation between words or line divisions.

FDA label imprint code

Information on whether an increase or decrease in score is the preferred result (e.g., a higher score indicates better quality OR a lower score indicates better quality OR quality is within a range).

Communication of an agent to a living subject via an undetermined route.

A code that is used to indicate the type of case safety report received from sender. The current code example reference is from the International Conference on Harmonisation (ICH) Expert Workgroup guideline on Clinical Safety Data Management: Data Elements for Transmission of Individual Case Safety Reports. The unknown/unavailable option allows the transmission of information from a secondary sender where the initial sender did not specify the type of report.

Example concepts include: Spontaneous, Report from study, Other.

Criteria for specifying the patients to be evaluated by a specific quality measure, based on a shared common set of characteristics (within a specific measurement set to which a given measure belongs). Details often include information based upon specific age groups, diagnoses, diagnostic and procedure codes, and enrollment periods.

Criteria for specifying the entities to be evaluated by a specific quality measure, based on a shared common set of characteristics (within a specific measurement set to which a given measure belongs).

The initial quantity of the specimen in inventory

An acute inpatient encounter.

A patient encounter where a patient is admitted by a hospital or equivalent facility, assigned to a location where patients generally stay at least overnight and provided with room, board, and continuous nursing service.

Any category of inpatient encounter except 'acute'

The requesting party has insufficient authorization to invoke the interaction.

Intermediate diagnoses are those diagnoses documented for administrative purposes during the course of a hospital stay.

Hypersensitivity resulting in an adverse reaction upon exposure to an agent.

Proposed therapy may be inappropriate or contraindicated because of a recorded patient intolerance to the proposed product. (Intolerances are non-immune based sensitivities.)

**Description:**The element does not follow the formatting or type rules defined for the field.

Accommodations used in the care of diseases that are transmitted through casual contact or respiratory transmission.

Describes the items counted by the measure (e.g., patients, encounters, procedures, etc.)

The list of jurisdiction(s) for which the measure applies.

A significant word that aids in discoverability.

Categorization of types of observation that capture the main clinical knowledge subject which may be a medication, a laboratory test, a disease.

Categorization of types of observation that capture a knowledge subtopic which might be treatment, etiology, or prognosis.

Proposed therapy may be inappropriate or contraindicated due to recent lab test results

**Description:**A note that is specific to a patient's laboratory results, either historical, current or planned.

Proposed therapy may be inappropriate or contraindicated when breast-feeding

Communication of an agent from one living subject to another living subject through direct contact with mammalian milk or colostrum.

**Description:**The length of the data specified is greater than the maximum length defined for the element.

**Description:**The length of the data specified is less than the minimum length defined for the element.

**Description:**The length of the data specified falls out of the range defined for the element.

An observation used to describe the Lipemia Index of the specimen. It is recommended to use the optical turbidity at 600 nm (in absorbance units).

FDA label logo

**Definition:**The set of LOINC codes for the act of determining the period of time that has elapsed since an entity was born or created.

Proposed dosage is below suggested therapeutic levels

Proposed dosage is below suggested therapeutic levels for the patient's age

Proposed dosage is below suggested therapeutic levels for the patient's height or body surface area

Proposed dosage is below suggested therapeutic levels for the patient's weight

**Description:**The specified element is mandatory and was not included in the instance.

**Description:**The maximum quantity of this drug allowed to be administered within a particular time-range (month, year, lifetime) has been reached or exceeded.

Defines the observation to be performed for each patient or event in the measure population. Measure observations for each case in the population are aggregated to determine the overall measure score for the population.

Examples:

• the median time from arrival in the Emergency Room to departure
• the median time from decision to admit to a hospital to the actual admission for Emergency Room patients

Criteria for specifying the measure population as a narrative description (e.g., all patients seen in the Emergency Department during the measurement period). This is used only in continuous variable eMeasures.

Criteria for specifying subjects who should be removed from the eMeasure's Initial Population and Measure Population. Measure Population Exclusions are used in Continuous Variable measures to help narrow the Measure Population before determining the value(s) of the continuous variable(s).

Indicates how the calculation is performed for the eMeasure (e.g., proportion, continuous variable, ratio)

Indicates whether the eMeasure is used to examine a process or an outcome over time (e.g., Structure, Process, Outcome).

The end date of the measurement period.

The time period for which the eMeasure applies.

The start date of the measurement period.

**Description:**A note that is specific to a patient's medications, either historical, current or planned.

Proposed therapy may interact with existing or recent natural health product therapy

The type of injury that the injury coding specifies.

**Definition:**The status of the request being fulfilled has changed such that it is no longer actionable. This may be because the request has expired, has already been completely fulfilled or has been otherwise stopped or disabled. (Not used for 'suspended' orders.)

Hypersensitivity to an agent caused by a mechanism other than an immunologic response to an initial exposure

Description: Metadata associated with the identification (e.g. name or gender) does not match the identification being verified.

Proposed therapy may interact with a non-prescription drug (e.g. alcohol, tobacco, Aspirin)

Communication of an agent from any entity to a living subject while the living subject is in the patient role in a healthcare facility.

**Definition:**The therapy being performed is not sufficiently equivalent to the therapy which was requested.

**Definition:**The therapy being performed is not generically equivalent (having the identical biological action) to the therapy which was requested.

**Definition:**The therapy being performed is not therapeutically equivalent (having the same overall patient effect) to the therapy which was requested.

Usage notes.

Criteria for specifying the processes or outcomes expected for each patient, procedure, or other unit of measurement defined in the denominator for proportion measures, or related to (but not directly derived from) the denominator for ratio measures (e.g., a numerator listing the number of central line blood stream infections and a denominator indicating the days per thousand of central line usage in a specific time period).

Criteria for specifying instances that should not be included in the numerator data. (e.g., if the number of central line blood stream infections per 1000 catheter days were to exclude infections with a specific bacterium, that bacterium would be listed as a numerator exclusion). Numerator Exclusions are used only in ratio eMeasures.

Proposed therapy may be inappropriate or contraindicated due to conditions or characteristics of the patient

An encounter where the patient usually will start in different encounter, such as one in the emergency department (EMER) but then transition to this type of encounter because they require a significant period of treatment and monitoring to determine whether or not their condition warrants an inpatient admission or discharge. In the majority of cases the decision about admission or discharge will occur within a time period determined by local, regional or national regulation, often between 24 and 48 hours.

Includes all codes defining types of indications such as diagnosis, symptom and other indications such as contrast agents for lab tests.

Distinguishes the kinds of coded observations that could be the trigger for clinical issue detection. These are observations that are not measurable, but instead can be defined with codes. Coded observation types include: Allergy, Intolerance, Medical Condition, Pregnancy status, etc.

Codes used to define various metadata aspects of a health quality measure.

Identifies the kinds of observations that can be performed

Description: One or more records in the query response have a status of 'obsolete'.

**Definition:**The therapy action is being performed outside the bounds of the time period requested

Communication of an agent from a living subject or environmental source to a living subject where the acquisition of the agent is not via the alimentary canal.

Indicates that the ICSR is describing problems that a patient experienced after receiving a vaccine product.

Description: Reporting codes that are related to an immunization event.

Proposed therapy is outside of the standard practice for a pediatric patient.

A similar or identical therapy was recently ordered by a different practitioner.

This patient was recently supplied a similar or identical therapy from a different pharmacy or supplier.

Observation types for specifying criteria used to assert that a subject is included in a particular population.

**Description:**The request is suspected to have a fraudulent basis.

A patient encounter where patient is scheduled or planned to receive service delivery in the future, and the patient is given a pre-admission account number. When the patient comes back for subsequent service, the pre-admission encounter is selected and is encapsulated into the service registration, and a new account number is generated.

Usage Note: This is intended to be used in advance of encounter types such as ambulatory, inpatient encounter, virtual, etc.

The dilution of the specimen made prior to being loaded onto analytical equipment

An observation about how important a preference is to the target of the preference.

Proposed therapy may be inappropriate or contraindicated during pregnancy

**Definition:**The same or similar treatment has previously been attempted with the patient without achieving a positive effect.

Accommodations in which there is only 1 bed.

Describes how to combine information calculated based on logic in each of several populations into one summarized result. It can also be used to describe how to risk adjust the data based on supplemental data elements described in the eMeasure. (e.g., pneumonia hospital measures antibiotic selection in the ICU versus non-ICU and then the roll-up of the two).

Open Issue: The description does NOT align well with the definition used in the HQMF specfication; correct the MSGAGG definition, and the possible distinction of MSRAGG as a child of AGGREGATE.

Succinct statement of the need for the measure. Usually includes statements pertaining to Importance criterion: impact, gap in care and evidence.

Proposed therapy may be inappropriate or contraindicated based on the potential for a patient reaction to the proposed product

Description: While the record was accepted in the repository, there is a more recent version of a record of this type.

Description: One or more records in the query response have been suppressed due to consent or privacy restrictions.

Identifies bibliographic citations or references to clinical practice guidelines, sources of evidence, or other relevant materials supporting the intent and rationale of the eMeasure.

The patient is receiving a subsequent fill significantly later than would be expected based on the amount previously supplied and the therapy dosage instructions

The patient is receiving a subsequent fill significantly earlier than would be expected based on the amount previously supplied and the therapy dosage instructions

Proposed therapy may be inappropriate or contraindicated because of a recorded patient allergy to a cross-sensitivity related product. (Allergies are immune based reactions.)

Proposed therapy may be inappropriate or contraindicated because of a recorded patient intolerance to a cross-sensitivity related product. (Intolerances are non-immune based sensitivities.)

Proposed therapy may be inappropriate or contraindicated because of a recorded prior adverse reaction to a cross-sensitivity related product.

Proposed therapy may be inappropriate or contraindicated because of a potential patient reaction to a cross-sensitivity related product.

A sequence of values in a "relative" time domain. The time is measured relative to the earliest effective time in the Observation Series containing this sequence.

**Description:**The number of repeating elements is above the maximum number of repetitions allowed.

**Description:**The number of repeating elements is below the minimum number of repetitions allowed.

**Description:**The number of repeating elements falls outside the range of the allowed number of repetitions.

Type of person or organization that is expected to report the issue.

**Description:**This observation represents an 'average' or 'expected' half-life typical of the product.

The value of the dilution of a sample after it had been analyzed at a prior dilution value

The method of adjusting for clinical severity and conditions present at the start of care that can influence patient outcomes for making valid comparisons of outcome measures across providers. Indicates whether an eMeasure is subject to the statistical process for reducing, removing, or clarifying the influences of confounding factors to allow more useful comparisons.